AMD

Algorithm could change way to treat wet AMDAn algorithm for guiding clinical judgments about the futility of anti-VEGF treatment of neovascular age-related macular degeneration (nvAMD) has importance from clinical, ethical, and legal perspectives and would be a valuable decision-making tool for retina specialists and payors, according to David T. Wong, MD.
Multiple strategies pursue treatment of dry AMDThere are a number of ongoing clinical trials investigating treatments for dry age-related macular degeneration (AMD). These modalities include medications that are already in use for other indications and investigational agents representing various novel mechanisms of action.
How do retinal specialists feel about OCT angiography?Ophthalmologists were asked what their plans were for using OCT angiography. You can participate in the survey and gain access to the full survey results by visiting www.practice-scope.com/#register.
Investigational wet AMD therapies aim for innovative targetsMany investigational drugs under development for the treatment of neovascular age-related macular degeneration (nvAMD) have advanced into the clinical trial stage, including several that are being evaluated in pivotal trials, said Peter K. Kaiser, MD.
Failed cell therapy study offers positives, raises new questionsPatients with a history of frequent anti-vascular endothelial growth factor (anti-VEGF) injections for the treatment of age-related macular degeneration (AMD) may not be the best potential candidates for encapsulated cell technology (ECT).
Treatment for geographic atrophy lacks efficacy in Phase 2 studyIn a placebo-controlled, dose-finding, proof-of-concept study conducted in patients with geographic atrophy secondary to age-related macular degeneration, an anti-amyloid β monoclonal antibody (GSK933776, GlaxoSmithKline) was safe and well-tolerated, but did not meet primary or secondary efficacy endpoints.
TREX-AMD trial finds visual gains from treat-and-extend vs. monthlyTreat-and-extend approach for neovascular AMD leads to beneficial results in 2-year clinical trial.
Transplantable 3-D retinas
Transplantable 3-D retinasAIVITA Biomedical has successfully engineered a three-dimensional transplantable retina construct and demonstrated connectivity and conductivity in an animal model of retinal degeneration.
System offers advanced capabilities in OCT, OCTAThe recent FDA clearance of a swept-source optical coherence tomography (OCT) and OCT angiography (OCTA) platform (PLEX Elite 9000, Carl Zeiss Meditec) for posterior ocular structures enables fast, dense, wide, and deep imaging of the retina, choroid, and their associated microvasculature, said Philip J. Rosenfeld, MD, PhD.
Seeing the reality of artificial vision
Seeing the reality of artificial visionOphthalmology may be one step closer to the hope of providing artificial vision for individuals affected by virtually all forms of blindness.